Therapeutic formulations for the treatment of beta-amyloid related diseases
First Claim
Patent Images
1. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-P disease, neurodegeneration, or cellular toxicity;
- and said second agent is a therapeutic drug or nutritive supplement.
3 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to methods and pharmaceutical compositions for treating amyloid-β related diseases, including Alzheimer'"'"'s disease. The invention, for example, includes a method of concomitant therapeutic treatment of a subject, comprising administering an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-β disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement.
-
Citations
391 Claims
- 1. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-P disease, neurodegeneration, or cellular toxicity;
-
2. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a first agent and a second agent, wherein said first agent prevents, or slows, or stops progression of an amyloid-β
- disease; and
said second agent is a therapeutic drug or nutritive supplement.
- disease; and
-
3. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent treats an amyloid-β
disease; and
said second agent is a therapeutic drug or nutritive supplement. - View Dependent Claims (45, 46)
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent treats an amyloid-β
-
4. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition, wherein said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, and wherein said pharmaceutical composition prevents, or slows, or stops progression of an amyloid-β
- disease in said subject.
-
5. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement, such that activities of daily living otherwise impaired by said amyloid-β
disease are improved or stabilized.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
6. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement, such that said pharmaceutical composition inhibits an interaction between an amyloidogenic protein and a glycoprotein or proteoglycan constituent of a basement membrane to thereby prevent or inhibit amyloid deposition.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
7. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement, such that the concentration of amyloid-β
or tau in the CSF of said subject changes versus an untreated subject.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
8. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
each of said second agent is a therapeutic drug or nutritive supplement.
- disease, said pharmaceutical composition comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
9. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
; and
said second agent is a therapeutic drug or nutritive supplement;
such that amyloid-β
fibril formation, neurodegeneration, or cellular toxicity in said subject is prevented or inhibited.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
-
10. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
; and
said second agent is a therapeutic drug or nutritive supplement;
such that cognitive function is stabilized or further deterioration in cognitive function is prevented, slowed, or stopped in said subject. - View Dependent Claims (35, 36)
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
-
11. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
; and
said second agent is a therapeutic drug or nutritive supplement;
such that activities of daily living otherwise impaired by said amyloid-β
disease are improved or stabilized in said subject.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
-
12. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
; and
said second agent is a therapeutic drug or nutritive supplement;
such that said pharmaceutical composition inhibits an interaction between an amyloidogenic protein and a glycoprotein or proteoglycan constituent of a basement membrane to thereby prevent or inhibit amyloid deposition in said subject.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
-
13. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
; and
said second agent is a therapeutic drug or nutritive supplement;
such that the concentration of amyloid-β
or tau in the CSF of said subject changes versus an untreated subject.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
-
14. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
; and
said second agent is a therapeutic drug or nutritive supplement;
such that amyloid-β
fibril formation, neurodegeneration, or cellular toxicity in said subject is prevented or inhibited.
- disease, said pharmaceutical composition comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
- 73. A pharmaceutical composition comprising a first agent in a first pharmaceutically acceptable carrier and a second agent in a second pharmaceutically acceptable carrier, wherein said first pharmaceutically acceptable carrier is different from said second pharmaceutically acceptable carrier.
-
74. A kit comprising a first pharmaceutical composition comprising a first agent in a pharmaceutically acceptable carrier and a second pharmaceutical composition comprising a second agent in a pharmaceutically acceptable carrier, wherein said first pharmaceutical composition is different from said second pharmaceutical composition.
-
75. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement. - View Dependent Claims (107, 114, 115, 116, 117, 118, 119, 120, 121, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346)
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
76. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement, such that cognitive function is stabilized or further deterioration in cognitive function is prevented, slowed, or stopped.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
77. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement, such that activities of daily living otherwise impaired by an amyloid-β
disease are improved or stabilized.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
78. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement, such that said pharmaceutical composition inhibits an interaction between an amyloidogenic protein and a glycoprotein or proteoglycan constituent of a basement membrane to thereby prevent or inhibit amyloid deposition.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
79. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement, such that the concentration of amyloid-β
or tau in the CSF of said subject changes versus an untreated subject.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
80. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
each of said second agent is a therapeutic drug or nutritive supplement.
- disease comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
81. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
; and
said second agent is a therapeutic drug or nutritive supplement;
such that amyloid-β
fibril formation, neurodegeneration, or cellular toxicity in said subject is prevented or inhibited. - View Dependent Claims (112, 113)
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
-
82. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
; and
said second agent is a therapeutic drug or nutritive supplement;
such that cognitive function is stabilized or further deterioration in cognitive function is prevented, slowed, or stopped in said subject.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
-
83. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
; and
said second agent is a therapeutic drug or nutritive supplement;
such that activities of daily living otherwise impaired by said amyloid-β
disease are improved or stabilized in said subject.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
-
84. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
; and
said second agent is a therapeutic drug or nutritive supplement;
such that said pharmaceutical composition inhibits an interaction between an amyloidogenic protein and a glycoprotein or proteoglycan constituent of a basement membrane to thereby prevent or inhibit amyloid deposition in said subject.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
-
85. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
; and
said second agent is a therapeutic drug or nutritive supplement;
such that the concentration of amyloid-β
or tau in the CSF of said subject changes versus an untreated subject.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
-
86. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
; and
said second agent is a therapeutic drug or nutritive supplement;
such that amyloid-β
fibril formation, neurodegeneration, or cellular toxicity in said subject is prevented or inhibited.
- disease comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent binds amyloid-β
-
111. The use of a first agent and a second agent in the preparation of a pharmaceutical composition for the treatment or prevention of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
240. The pharmaceutical composition of 235, wherein said substituted or unsubstituted alkanesulfonic acid is a substituted or unsubstituted straight-chain alkanesulfonic acid, substituted or unsubstituted cycloalkanesulfonic acid, substituted or unsubstituted branched-chain alkanesulfonic acid.
-
347. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a first agent for treating or preventing an amyloid-β
- disease and a second agent, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement.
- disease and a second agent, wherein said first agent prevents or inhibits amyloid-β
-
348. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a first agent for treating or preventing an amyloid-β
- disease and a second agent, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement, such that cognitive function is stabilized or further deterioration in cognitive function is prevented, slowed, or stopped.
- disease and a second agent, wherein said first agent prevents or inhibits amyloid-β
-
349. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
350. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
fibril formation, neurodegeneration, or cellular toxicity; and
said second agent is a therapeutic drug or nutritive supplement, such that cognitive function is stabilized or further deterioration in cognitive function is prevented, slowed, or stopped.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or inhibits amyloid-β
-
351. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement, such that activities of daily living otherwise impaired by said amyloid-β
disease are improved or stabilized.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
352. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement, such that said pharmaceutical composition inhibits an interaction between an amyloidogenic protein and a glycoprotein or proteoglycan constituent of a basement membrane to thereby prevent or inhibit amyloid deposition.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
353. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement, such that the concentration of amyloid-β
or tau in the CSF of said subject changes versus an untreated subject.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
354. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
each of said second agent is a therapeutic drug or nutritive supplement.
- disease, said pharmaceutical composition comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
355. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement;
such that amyloid-β
fibril formation, neurodegeneration, or cellular toxicity in said subject is prevented or inhibited.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
356. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement;
such that cognitive function is stabilized or further deterioration in cognitive function is prevented, slowed, or stopped in said subject.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
357. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement;
such that activities of daily living otherwise impaired by said amyloid-β
disease are improved or stabilized in said subject.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
358. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement;
such that said pharmaceutical composition inhibits an interaction between an amyloidogenic protein and a glycoprotein or proteoglycan constituent of a basement membrane to thereby prevent or inhibit amyloid deposition in said subject.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
359. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement;
such that the concentration of amyloid-β
or tau in the CSF of said subject changes versus an untreated subject.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
360. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement;
such that amyloid-β
fibril formation, neurodegeneration, or cellular toxicity in said subject is prevented or inhibited.
- disease, said pharmaceutical composition comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
361. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
362. A pharmaceutical composition for the treatment of an amyloid-P disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
- related disease; and
said second agent is a therapeutic drug or nutritive supplement, such that cognitive function is stabilized or further deterioration in cognitive function is prevented, slowed, or stopped.
- related disease; and
-
363. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement, such that activities of daily living otherwise impaired by an anyloid-β
disease are improved or stabilized.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
364. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement, such that said pharmaceutical composition inhibits an interaction between an amyloidogenic protein and a glycoprotein or proteoglycan constituent of a basement membrane to thereby prevent or inhibit amyloid deposition.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
365. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement, such that the concentration of amyloid-β
or tau in the CSF of said subject changes versus an untreated subject.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
366. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
each of said second agent is a therapeutic drug or nutritive supplement.
- disease comprising a first agent and at least two second agents in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
367. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement, such that the level of amyloid-β
in the CSF of the subject is decreased versus an untreated subject.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
368. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement, such that the level of amyloid-β
in the CSF or the plasma of the subject is decreased versus an untreated subject.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
369. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement, such that the level of amyloid-β
in the plasma of the subject is modulated versus an untreated subject.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
370. A pharmaceutical composition for the treatment of an amyloid-β
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
related disease; and
said second agent is a therapeutic drug or nutritive supplement, such that the level of amyloid-β
in the CSF or the plasma of the subject is decreased or modulated versus an untreated subject.
- disease comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent prevents or treats amyloid-β
-
371. A method of preventing or treating an amyloid-β
- related disease in a subject, said method comprising administering to a subject in need thereof an effective amount of a first agent that prevents or treats amyloid-β
related disease, and a second agent that is a therapeutic drug or nutritive supplement. - View Dependent Claims (372, 376)
- related disease in a subject, said method comprising administering to a subject in need thereof an effective amount of a first agent that prevents or treats amyloid-β
- 373. A method for preventing or treating Alzheimer'"'"'s disease in a subject, said method comprising administering to a subject in need thereof an effective amount of a first agent that prevents or treats Alzheimer'"'"'s disease, and a second agent that is a therapeutic drug or nutritive supplement.
- 377. A method of preventing or treating Alzheimer'"'"'s disease comprising concomitantly administering to a subject in need thereof an effective amount of a first agent that is efficacious in preventing or treating Alzheimer'"'"'s disease in said subject and a second agent, wherein said first agent comprises 3-amino-1-propanesulfonic acid or a pharmaceutically acceptable salt thereof.
-
378. A method of preventing or treating Mild Cognitive Impairment comprising concomitantly administering to a subject in need thereof an effective amount of a first agent that is efficacious in preventing or treating Mild Cognitive Impairment in said subject and a second agent, wherein said first agent comprises 3-amino-1-propanesulfonic acid or a pharmaceutically acceptable salt thereof.
-
379. A method of preventing or treating Alzheimer'"'"'s disease comprising concomitantly administering to a subject in need thereof an effective amount of a first agent that is efficacious in preventing or treating Alzheimer'"'"'s disease in said subject and a second agent, wherein said first agent is 3-amino-1-propanesulfonic acid.
-
380. A method of preventing or treating Mild Cognitive Impairment comprising concomitantly administering to a subject in need thereof an effective amount of a first agent that is efficacious in preventing or treating Mild Cognitive Impairment in said subject and a second agent, wherein said first agent is 3-amino-1-propanesulfonic acid.
- 384. A pharmaceutical composition for preventing or treating Alzheimer'"'"'s disease comprising an effective amount of a first agent that is efficacious in preventing or treating Alzheimer'"'"'s disease in said subject and a second agent, wherein said first agent comprises 3-amino-1-propanesulfonic acid or a pharmaceutically acceptable salt thereof.
-
385. A pharmaceutical composition for preventing or treating Mild Cognitive Impairment comprising an effective amount of a first agent that is efficacious in preventing or treating Mild Cognitive Impairment in said subject and a second agent, wherein said first agent comprises 3-amino-1-propanesulfonic acid or a pharmaceutically acceptable salt thereof.
-
386. A pharmaceutical composition for preventing or treating Alzheimer'"'"'s disease comprising an effective amount of a first agent that is efficacious in preventing or treating Alzheimer'"'"'s disease in said subject and a second agent, wherein said first agent is 3-amino-1-propanesulfonic acid.
-
387. A pharmaceutical composition for preventing or treating Mild Cognitive Impairment comprising an effective amount of a first agent that is efficacious in preventing or treating Mild Cognitive Impairment in said subject and a second agent, wherein said first agent is 3-amino-1-propanesulfonic acid.
-
391. A method of concomitant therapeutic treatment of a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition for treating or preventing an amyloid-β
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent modulates amyloid-β
levels in the plasma or CSF; and
said second agent is a therapeutic drug or nutritive supplement.
- disease, said pharmaceutical composition comprising a first agent and a second agent in a pharmaceutically acceptable carrier, wherein said first agent modulates amyloid-β
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeBellus Health (Interational) Limited (GSK plc)
-
Original AssigneeBellus Health (Interational) Limited (GSK plc)
-
InventorsBellini, Francesco, Gervais, Francine
-
Application NumberUS10/871,537Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current424/400CPC Class CodesA61K 45/06 Mixtures of active ingredie...
